Mishra, Asmita http://orcid.org/0000-0003-3065-4294
Pidala, Joseph
Thapa, Ram
Betts, Brian C.
Fernandez, Hugo
Locke, Frederick L. http://orcid.org/0000-0001-9063-6691
Nishihori, Taiga http://orcid.org/0000-0002-2621-7924
Perez, Lia
Wang, Xuefeng
Anasetti, Claudio
Jim, Heather http://orcid.org/0000-0001-7353-3711
Article History
Received: 29 January 2021
Revised: 15 July 2021
Accepted: 29 July 2021
First Online: 11 August 2021
Competing interests
: AM receives grant funding from Novartis. BCB is a co-inventor for provisional patents related to the use of the CD83 CAR T cells (WO2019165156), JAK inhibitors (WO2017058950A1), and STAT3 inhibitors (WO2015120436A2) in GVHD prevention and treatment; BCB nor his institution(s) have received payment related to claims described in the patents. HF is on the advisory boards for Incyte and Jazz and speakers bureau for Sanofi. FLL is a scientific advisor for Kite/Gilead, Novartis, BMS/Celgene, Allogene, Wugen, Calibr, and GammaDelta Therapeutics, is a consultant for Cellular BioMedicine Group Inc., and has institutional patents for Survivin Dendritic Cell Vaccine; improving CAR T Cell Therapy. TN receives research support to the institution (not to the individual) from Novartis and Karyopharm. HJ consulted for RedHill BioPharma, Janssen Scientific Affairs, and Merck. The other authors declare no competing interests.